Analgesic effect of highly reversible ω-conotoxin FVIA on N type Ca2+ channels

Molecular Pain

Volumn 6, Issue , 2010, Pages

  Lee, Seungkyu ^a   Kim, Yoonji ^e   Back, Seung Keun ^c   Choi, Hee Woo ^d   Lee, Ju Yeon ^a   Jung, Hyun Ho ^a   Ryu, Jae Ha ^a   Suh, Hong Won ^d   Na, Heung Sik ^c   Kim, Hyun Jeong ^b   Rhim, Hyewhon ^e   Kim, Jae Il ^a  

^a Gwangju Institute of Science and Technology (GIST)   (South Korea)

^b Seoul National University   (South Korea)

^c Korea University College of Medicine   (South Korea)

^d Hallym University   (South Korea)

^e Korea Institute of Science and Technology   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL N TYPE; OMEGA CONOTOXIN; OMEGA CONOTOXIN FVIA; OMEGA CONOTOXIN MVIIA; UNCLASSIFIED DRUG; ANALGESIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; OMEGA CONOTOXIN MVIIA, CONUS FULMEN; OMEGA-CONOTOXIN-MVIIA, CONUS FULMEN;

ALLODYNIA; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; CONUS SNAIL; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; EMBRYO; HUMAN; HUMAN CELL; LOW DRUG DOSE; MALE; MEAN ARTERIAL PRESSURE; MOUSE; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; PAIN; PRIORITY JOURNAL; RAT; WRITHING TEST; ANIMAL; BLOOD PRESSURE; DOSE RESPONSE; DRUG EFFECT; HEAT; ISOLATION AND PURIFICATION; SPRAGUE DAWLEY RAT;

ANALGESICS, NON-NARCOTIC; ANIMALS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, N-TYPE; DOSE-RESPONSE RELATIONSHIP, DRUG; HOT TEMPERATURE; MALE; MICE; OMEGA-CONOTOXINS; PAIN; RATS; RATS, SPRAGUE-DAWLEY;

EID: 78650263683     PISSN: None     EISSN: 17448069     Source Type: Journal    
DOI: 10.1186/1744-8069-6-97     Document Type: Article

References (67)

1. Cao YQ. Voltage-gated calcium channels and pain. Pain 2006, 126:5-9. 10.1016/j.pain.2006.10.019, 17084979.
2. Chaplan SR. Neuropathic pain: role of voltage-dependent calcium channels. Reg Anesth Pain Med 2000, 25:283-285.
3. Altier C, Zamponi GW. Targeting Ca2+ channels to treat pain: T-type versus N-type. Trends Pharmacol Sci 2004, 25:465-470. 10.1016/j.tips.2004.07.004, 15559248.
4. Snutch TP. Targeting chronic and neuropathic pain: the N-type calcium channel comes of age. NeuroRx 2005, 2:662-670. 10.1602/neurorx.2.4.662, 1201323, 16489373.
5. Norton RS, McDonough SI. Peptides targeting voltage-gated calcium channels. Curr Pharm Des 2008, 14:2480-2491. 10.2174/138161208785777478, 18781996.
6. Scott DA, Wright CE, Angus JA. Actions of intrathecal omega-conotoxins CVID, GVIA, MVIIA, and morphine in acute and neuropathic pain in the rat. Eur J Pharmacol 2002, 451:279-286. 10.1016/S0014-2999(02)02247-1, 12242089.
7. Dai Q, Liu F, Zhou Y, Lu B, Yu F, Huang P. The synthesis of SO-3, a conopeptide with high analgesic activity derived from Conus striatus. J Nat Prod 2003, 66:1276-1279. 10.1021/np030099y, 14510617.
8. Yan LD, Liu YL, Zhang L, Dong HJ, Zhou PL, Su RB, et al. Spinal antinociception of synthetic omega-conotoxin SO-3, a selective N-type neuronal voltage-sensitive calcium channel blocker, and its effects on morphine analgesia in chemical stimulus tests in rodent. Eur J Pharmacol 2010, 636:73-81. 10.1016/j.ejphar.2010.03.036, 20361956.
9. Garber K. Peptide leads new class of chronic pain drugs. Nat Biotechnol 2005, 23:399. 10.1038/nbt0405-399, 15815650.
10. Staats PS, Yearwood T, Charapata SG, Presley RW, Wallace MS, Byas-Smith M, et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA 2004, 291:63-70. 10.1001/jama.291.1.63, 14709577.
11. Malmberg AB, Yaksh TL. Effect of Continuous Intrathecal Infusion of Omega-Conopeptides, N-Type Calcium-Channel Blockers, on Behavior and Antinociception in the Formalin and Hot-Plate Tests in Rats. Pain 1995, 60:83-90. 10.1016/0304-3959(94)00094-U, 7715945.
12. Penn RD, Paice JA. Adverse effects associated with the intrathecal administration of ziconotide. Pain 2000, 85:291-296. 10.1016/S0304-3959(99)00254-7, 10692631.
13. Prommer EE. Ziconotide: can we use it in palliative care?. Am J Hosp Palliat Care 2005, 22:369-374. 10.1177/104990910502200510, 16225359.
14. Prommer E. Ziconotide: a new option for refractory pain. Drugs Today (Barc) 2006, 42:369-378. 10.1358/dot.2006.42.6.973534, 16845440.
15. Jain KK. An evaluation of intrathecal ziconotide for the treatment of chronic pain. Expert Opin Investig Drugs 2000, 9:2403-2410. 10.1517/13543784.9.10.2403, 11060815.
16. Williams JA, Day M, Heavner JE. Ziconotide: an update and review. Expert Opin Pharmacother 2008, 9:1575-1583. 10.1517/14656566.9.9.1575, 18518786.
17. Swinney DC. Can Binding kinetics translate to a clinically differentiated drug? from theory to practice. Letters in Drug Design & Discovery 2006, 3:569-574.
18. Zhang R, Monsma F. The importance of drug-target residence time. Curr Opin Drug Discov Devel 2009, 12:488-496.
19. Pruneau D, Angus JA. Omega-conotoxin GVIA, the N-type calcium channel inhibitor, is sympatholytic but not vagolytic: consequences for hemodynamics and autonomic reflexes in conscious rabbits. J Cardiovasc Pharmacol 1990, 16:675-680. 10.1097/00005344-199010000-00022, 1706812.
20. Mould J, Yasuda T, Schroeder CI, Beedle AM, Doering CJ, Zamponi GW, et al. The alpha2delta auxiliary subunit reduces affinity of omega-conotoxins for recombinant N-type (Cav2.2) calcium channels. J Biol Chem 2004, 279:34705-34714. 10.1074/jbc.M310848200, 15166237.
21. Smith MT, Cabot PJ, Ross FB, Robertson AD, Lewis RJ. The novel N-type calcium channel blocker, AM336, produces potent dose-dependent antinociception after intrathecal dosing in rats and inhibits substance P release in rat spinal cord slices. Pain 2002, 96:119-127. 10.1016/S0304-3959(01)00436-5, 11932068.
22. Schoenfeld RA. The Genomic Structure of Delta-conotoxins and other O-superfamily Conotoxins 1999, University of Utah: Ph.D. thesis.
23. Buczek O, Bulaj G, Olivera BM. Conotoxins and the posttranslational modification of secreted gene products. Cell Mol Life Sci 2005, 62:3067-3079. 10.1007/s00018-005-5283-0, 16314929.
24. Nielsen KJ, Schroeder T, Lewis R. Structure-activity relationships of omega-conotoxins at N-type voltage-sensitive calcium channels. J Mol Recognit 2000, 13:55-70. 10.1002/(SICI)1099-1352(200003/04)13:2<55::AID-JMR488>3.0.CO;2-O, 10822250.
25. McNaughton NC, Randall AD. Electrophysiological properties of the human N-type Ca2+ channel: I. Channel gating in Ca2+, Ba2+ and Sr2+ containing solutions. Neuropharmacology 1997, 36:895-915. 10.1016/S0028-3908(97)00085-3, 9257935.
26. Wen L, Yang S, Qiao H, Liu Z, Zhou W, Zhang Y, et al. SO-3, a new O-superfamily conopeptide derived from Conus striatus, selectively inhibits N-type calcium currents in cultured hippocampal neurons. Br J Pharmacol 2005, 145:728-739. 10.1038/sj.bjp.0706223, 1576188, 15880145.
27. Lewis RJ, Nielsen KJ, Craik DJ, Loughnan ML, Adams DA, Sharpe IA, et al. Novel omega-conotoxins from Conus catus discriminate among neuronal calcium channel subtypes. J Biol Chem 2000, 275:35335-35344. 10.1074/jbc.M002252200, 10938268.
28. Feng ZP, Doering CJ, Winkfein RJ, Beedle AM, Spafford JD, Zamponi GW. Determinants of inhibition of transiently expressed voltage-gated calcium channels by omega-conotoxins GVIA and MVIIA. J Biol Chem 2003, 278:20171-20178. 10.1074/jbc.M300581200, 12654924.
29. Hunskaar S, Fasmer OB, Hole K. Formalin test in mice, a useful technique for evaluating mild analgesics. J Neurosci Methods 1985, 14:69-76. 10.1016/0165-0270(85)90116-5, 4033190.
30. Cowan A, Porreca F, Wheeler H. Use of the formalin test in evaluating analgesics. NIDA Res Monogr 1989, 95:116-122.
31. Na HS, Han JS, Ko KH, Hong SK. A behavioral model for peripheral neuropathy produced in rat's tail by inferior caudal trunk injury. Neurosci Lett 1994, 177:50-52. 10.1016/0304-3940(94)90042-6, 7824181.
32. Hirning LD, Fox AP, McCleskey EW, Olivera BM, Thayer SA, Miller RJ, et al. Dominant role of N-type Ca2+ channels in evoked release of norepinephrine from sympathetic neurons. Science 1988, 239:57-61. 10.1126/science.2447647, 2447647.
33. Terlau H, Olivera BM. Conus venoms: a rich source of novel ion channel-targeted peptides. Physiol Rev 2004, 84:41-68. 10.1152/physrev.00020.2003, 14715910.
34. Lewis RJ, Garcia ML. Therapeutic potential of venom peptides. Nat Rev Drug Discov 2003, 2:790-802. 10.1038/nrd1197, 14526382.
35. Olivera BM, Cruz LJ, de S V, LeCheminant GW, Griffin D, Zeikus R, et al. Neuronal calcium channel antagonists. Discrimination between calcium channel subtypes using omega-conotoxin from Conus magus venom. Biochemistry 1987, 26:2086-2090. 10.1021/bi00382a004, 2441741.
36. Feng ZP, Hamid J, Doering C, Bosey GM, Snutch TP, Zamponi GW. Residue Gly1326 of the N-type calcium channel alpha 1B subunit controls reversibility of omega-conotoxin GVIA and MVIIA block. J Biol Chem 2001, 276:15728-15735. 10.1074/jbc.M100406200, 11279062.
37. Abe M, Kurihara T, Han W, Shinomiya K, Tanabe T. Changes in expression of voltage-dependent ion channel subunits in dorsal root ganglia of rats with radicular injury and pain. Spine (Phila Pa 1976) 2002, 27:1517-1524.
38. Newton RA, Bingham S, Case PC, Sanger GJ, Lawson SN. Dorsal root ganglion neurons show increased expression of the calcium channel alpha2delta-1 subunit following partial sciatic nerve injury. Brain Res Mol Brain Res 2001, 95:1-8. 10.1016/S0169-328X(01)00188-7, 11687271.
39. Liang H, Elmslie KS. Rapid and reversible block of N-type calcium channels (CaV 2.2) by omega-conotoxin GVIA in the absence of divalent cations. J Neurosci 2002, 22:8884-8890.
40. Sato K, Raymond C, Martin-Moutot N, Sasaki T, Omori A, Ohtake A, et al. Binding of chimeric analogs of omega-conotoxin MVIIA and MVIIC to the N- and P/Q-type calcium channels. FEBS Lett 1997, 414:480-484. 10.1016/S0014-5793(97)01056-9, 9315745.
41. Stocker JW, Nadasdi L, Aldrich RW, Tsien RW. Preferential interaction of omega-conotoxins with inactivated N-type Ca2+ channels. J Neurosci 1997, 17:3002-3013.
42. McGivern JG. Ziconotide: a review of its pharmacology and use in the treatment of pain. Neuropsychiatr Dis Treat 2007, 3:69-85. 10.2147/nedt.2007.3.1.69, 2654521, 19300539.
43. Scholz J, Woolf CJ. Can we conquer pain?. Nat Neurosci 2002, 5(Suppl):1062-1067. 10.1038/nn942, 12403987.
44. Cizkova D, Marsala J, Lukacova N, Marsala M, Jergova S, Orendacova J, et al. Localization of N-type Ca2+ channels in the rat spinal cord following chronic constrictive nerve injury. Exp Brain Res 2002, 147:456-463. 10.1007/s00221-002-1217-3, 12444477.
45. Hogan Q. Animal pain models. Reg Anesth Pain Med 2002, 27:385-401.
46. Wang LX, Wang ZJ. Animal and cellular models of chronic pain. Adv Drug Deliv Rev 2003, 55:949-965. 10.1016/S0169-409X(03)00098-X, 12935939.
47. Choi SS, Lee JK, Suh HW. Antinociceptive profiles of aspirin and acetaminophen in formalin, substance P and glutamate pain models. Brain Res 2001, 921:233-239. 10.1016/S0006-8993(01)03126-2, 11720731.
48. Haley JE, Sullivan AF, Dickenson AH. Evidence for spinal N-methyl-D-aspartate receptor involvement in prolonged chemical nociception in the rat. Brain Res 1990, 518:218-226. 10.1016/0006-8993(90)90975-H, 1975214.
49. Reeve AJ, Patel S, Fox A, Walker K, Urban L. Intrathecally administered endotoxin or cytokines produce allodynia, hyperalgesia and changes in spinal cord neuronal responses to nociceptive stimuli in the rat. Eur J Pain 2000, 4:247-257. 10.1053/eujp.2000.0177, 10985868.
50. Czeschik JC, Hagenacker T, Schafers M, Busselberg D. TNF-alpha differentially modulates ion channels of nociceptive neurons. Neurosci Lett 2008, 434:293-298. 10.1016/j.neulet.2008.01.070, 18314270.
51. Hagenacker T, Czeschik JC, Schafers M, Busselberg D. Sensitization of voltage activated calcium channel currents for capsaicin in nociceptive neurons by tumor-necrosis-factor-alpha. Brain Res Bull 2010, 81:157-163. 10.1016/j.brainresbull.2009.09.012, 19818386.
52. Czeschik JC, Hagenacker T, Schafers M, Busselberg D. TNF-alpha differentially modulates ion channels of nociceptive neurons. Neurosci Lett 2008, 434:293-298. 10.1016/j.neulet.2008.01.070, 18314270.
53. Binshtok AM, Wang H, Zimmermann K, Amaya F, Vardeh D, Shi L, et al. Nociceptors are interleukin-1beta sensors. J Neurosci 2008, 28:14062-14073. 10.1523/JNEUROSCI.3795-08.2008, 2690713, 19109489.
54. Julius D, Basbaum AI. Molecular mechanisms of nociception. Nature 2001, 413:203-210. 10.1038/35093019, 11557989.
55. Yamamoto T, Sakashita Y. Differential effects of intrathecally administered N- and P-type voltage-sensitive calcium channel blockers upon two models of experimental mononeuropathy in the rat. Brain Research 1998, 794:329-332. 10.1016/S0006-8993(98)00306-0, 9622667.
56. Matthews EA, Dickenson AH. Effects of spinally delivered N- and P-type voltage-dependent calcium channel antagonists on dorsal horn neuronal responses in a rat model of neuropathy. Pain 2001, 92:235-246. 10.1016/S0304-3959(01)00255-X, 11323145.
57. Kim JI, Takahashi M, Ogura A, Kohno T, Kudo Y, Sato K. Hydroxyl group of Tyr13 is essential for the activity of omega-conotoxin GVIA, a peptide toxin for N-type calcium channel. J Biol Chem 1994, 269:23876-23878.
58. Kim JI, Takahashi M, Ohtake A, Wakamiya A, Sato K. Tyr13 is essential for the activity of omega-conotoxin MVIIA and GVIA, specific N-type calcium channel blockers. Biochem Biophys Res Commun 1995, 206:449-454. 10.1006/bbrc.1995.1063, 7826361.
59. Nadasdi L, Yamashiro D, Chung D, Tarczy-Hornoch K, Adriaenssens P, Ramachandran J. Structure-activity analysis of a Conus peptide blocker of N-type neuronal calcium channels. Biochemistry 1995, 34:8076-8081. 10.1021/bi00025a013, 7794920.
60. Wright CE, Robertson AD, Whorlow SL, Angus JA. Cardiovascular and autonomic effects of omega-conotoxins MVIIA and CVID in conscious rabbits and isolated tissue assays. Br J Pharmacol 2000, 131:1325-1336. 10.1038/sj.bjp.0703701, 1572459, 11090104.
61. Copeland RA, Pompliano DL, Meek TD. Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov 2006, 5:730-739. 10.1038/nrd2082, 16888652.
62. McOrist AL, Jackson M, Bird AR. A comparison of five methods for extraction of bacterial DNA from human faecal samples. J Microbiol Methods 2002, 50:131-139. 10.1016/S0167-7012(02)00018-0, 11997164.
63. Hylden JL, Wilcox GL. Intrathecal morphine in mice: a new technique. Eur J Pharmacol 1980, 67:313-316. 10.1016/0014-2999(80)90515-4, 6893963.
64. Hylden JL, Wilcox GL. Intrathecal substance P elicits a caudally-directed biting and scratching behavior in mice. Brain Res 1981, 217:212-215. 10.1016/0006-8993(81)90203-1, 6167328.
65. Kim HJ, Na HS, Sung B, Nam HJ, Chung YJ, Hong SK. Is sympathetic sprouting in the dorsal root ganglia responsible for the production of neuropathic pain in a rat model?. Neurosci Lett 1999, 269:103-106. 10.1016/S0304-3940(99)00435-8, 10430515.
66. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 1994, 53:55-63. 10.1016/0165-0270(94)90144-9, 7990513.
67. Widdop RE, Li XC. A simple versatile method for measuring tail cuff systolic blood pressure in conscious rats. Clin Sci (Lond) 1997, 93:191-194.